Vaginal Dryness, Bladder Urgency, and Pain with Sex Are Not Just “Part of Aging”

Vaginal Dryness, Bladder Urgency, and Pain with Sex Are Not Just “Part of Aging”

Genitourinary syndrome of menopause — what it is, why it happens, and what actually treats it

There is a conversation that happens in exam rooms millions of times a year and almost never goes anywhere productive.

A woman in her 40s or 50s mentions — often quietly, often after bringing up something else first — that sex has become painful. Or that she’s rushing to the bathroom more than she used to. Or that the urgency sometimes doesn’t wait. Or that something has shifted in the tissue itself — a dryness, a rawness, a loss of the comfortable, well-lubricated baseline she used to take for granted.

The response she receives is often some version of: “That’s normal at your age. Use a lubricant.”

This is not adequate. It is not adequate clinically, because these symptoms have a specific biological mechanism that is well understood and highly treatable. And it is not adequate for the woman sitting in that room, who has just been told that a significant change in her quality of life — in her physical comfort, her sexual function, her bladder control, her relationship — is simply what getting older looks like now.

Genitourinary syndrome of menopause — GSM — is the clinical term for this cluster of symptoms. It affects the majority of women in the menopause transition and beyond. It is underreported, undertreated, and progressive when it’s not addressed. And it responds very well to treatment when treatment is offered.

What genitourinary syndrome of menopause actually is

GSM replaced the older term “vaginal atrophy” in the medical literature because the older term captured only part of what’s happening. The syndrome involves not just the vaginal tissue but the entire genitourinary system — vulva, vagina, urethra, and bladder — all of which are estrogen-dependent tissues that undergo structural and functional changes as estrogen declines.

The symptoms of GSM fall into three overlapping categories:

Vaginal and vulvar symptoms

• Vaginal dryness — loss of the natural lubrication that keeps vaginal tissue comfortable at baseline, not only during sex

• Vaginal narrowing and shortening — the vaginal canal itself becomes less elastic and may shorten over time without estrogen support

• Vulvar irritation, burning, or rawness — without adequate estrogen, the vulvar tissue thins and becomes more sensitive and reactive

• Discharge changes — vaginal pH rises without estrogen, altering the microbiome and sometimes producing discharge that is different in character or odor

• Spotting or bleeding — fragile, thinned tissue may bleed with minor friction or even without apparent cause

Sexual symptoms

• Pain with intercourse (dyspareunia) — ranging from mild discomfort to severe pain, caused by tissue thinning, loss of lubrication, and reduced elasticity

• Tearing or bleeding with intercourse — fragile estrogen-depleted tissue is more prone to micro-tears, which may bleed and cause pain after sex

• Reduced or absent arousal response — estrogen and testosterone both contribute to genital engorgement and lubrication during arousal. As both decline, the arousal response slows, diminishes, or becomes absent, even with adequate desire

• Reduced sensation — nerve endings in genital tissue are estrogen-sensitive; their function declines as tissue thins and blood flow decreases

• Difficulty reaching orgasm — reduced tissue sensitivity, reduced blood flow, and reduced arousal response all contribute to orgasm becoming more difficult, less intense, or absent

• Decreased libido — while low libido in perimenopause has multiple drivers including testosterone decline, fatigue, and mood changes, the discomfort of GSM itself creates an avoidance pattern that compounds the underlying hormonal reduction in desire

Bladder and urinary symptoms

• Urinary urgency — a sudden, compelling need to urinate that may be difficult to defer, not caused by bladder infection

• Urinary frequency — needing to urinate more often than usual during the day

• Nocturia — waking at night to urinate, often multiple times

• Urge incontinence — leaking urine before reaching the bathroom, driven by urgency

• Stress incontinence — leaking urine with coughing, sneezing, laughing, or exercise, related to pelvic floor collagen loss

• Recurrent urinary tract infections — the urethral tissue and bladder lining are estrogen-dependent; as they thin and the vaginal microbiome shifts, the barrier to bacterial colonization weakens significantly, leading to recurrent UTIs that may be resistant to the usual treatment approach

The biology — why estrogen loss causes all of this

The vulva, vagina, urethra, and bladder all contain high concentrations of estrogen receptors. Estrogen maintains these tissues in a specific state: well-hydrated, elastic, well-vascularized, and colonized by a protective lactobacillus-dominant microbiome that keeps vaginal pH acidic and resistant to pathogenic bacteria.

When estrogen declines, all of these maintenance functions are withdrawn simultaneously:

• Collagen loss — the connective tissue framework of vaginal, vulvar, and urethral tissue depends on estrogen-stimulated collagen production. Loss of estrogen means loss of tissue thickness, elasticity, and structural integrity across the entire genitourinary system.

• Reduced blood flow — estrogen promotes vasodilation and blood flow to genital tissue. Reduced blood flow means less oxygen and nutrient delivery to tissue, slower healing, reduced arousal response, and diminished sensation. This is the vascular component that contributes to arousal difficulty and reduced orgasmic response.

• Loss of vaginal lubrication — vaginal lubrication is produced by transudate from blood vessels in the vaginal wall. Reduced blood flow and thinned tissue means less transudate and therefore less baseline and arousal lubrication.

• Microbiome shift — estrogen supports glycogen production in vaginal epithelial cells, which feeds lactobacillus bacteria. Without estrogen, glycogen drops, lactobacillus declines, vaginal pH rises from its normal acidic 3.5–4.5 toward neutral or alkaline, and opportunistic bacteria and yeast establish more easily.

• Urethral and bladder lining thinning — the urethra and bladder trigone (the base of the bladder) are particularly estrogen-sensitive. As their lining thins, the threshold for urgency signals drops, the barrier to bacterial entry weakens, and symptoms of urgency, frequency, and recurrent infection increase.

Why GSM is underreported and undertreated

Studies consistently show that the majority of women with GSM symptoms do not discuss them with their healthcare provider, and that when they do, they frequently receive inadequate or no treatment. Several factors contribute to this gap:

• Normalization — women are told, and come to believe, that vaginal dryness, painful sex, and bladder urgency are normal consequences of aging that must be accepted. They are not. They are the consequences of estrogen deficiency, which is treatable.

• Shame and embarrassment — genitourinary and sexual symptoms carry social stigma that makes them harder to raise in clinical encounters. Women may minimize or not mention symptoms they find embarrassing, particularly around sexual function and incontinence.

• Provider discomfort — many healthcare providers are not trained to proactively ask about genitourinary symptoms or are uncomfortable discussing sexual function. These symptoms are frequently not screened for unless the patient raises them.

• Lack of awareness of treatment options — many women and some providers are not aware that safe, effective, locally-applied treatments exist for GSM, or that systemic hormone therapy also addresses these symptoms. The belief that nothing can be done leads to no conversation happening at all.

• Fear of hormones — women who have internalized the overstated risks from the 2002 WHI study may decline treatment out of fear, not knowing that vaginal estrogen carries negligible systemic absorption and is not associated with the risks attributed to systemic hormone therapy.

An important note on recurrent UTIs:

Many women in perimenopause and menopause experience recurrent UTIs and are treated repeatedly with antibiotics without anyone asking why they keep occurring. The answer is frequently genitourinary atrophy — thinned, low-estrogen urethral and bladder tissue that provides less barrier protection. Treating the underlying estrogen deficiency, typically with vaginal estrogen, dramatically reduces UTI recurrence for most women. If you have had two or more UTIs in the past year, this is worth discussing with your provider.

GSM is progressive without treatment.

Unlike hot flashes, which often diminish over time, genitourinary symptoms typically worsen as the years without estrogen support accumulate. Tissue that has been estrogen-deprived for years is harder to restore than tissue addressed early in the transition. This is one of the strongest arguments for not waiting — intervention earlier in the transition preserves tissue health more effectively than attempting restoration later.

A woman who is told to “live with it” at 48 is likely to have significantly more difficult-to-treat symptoms at 58 if nothing changes.

What actually treats GSM

GSM is one of the most treatable conditions in women’s hormone health. The treatments are safe, effective, and in many cases produce significant symptom relief within weeks. Unlike hot flashes, which may resolve on their own over time, GSM requires ongoing treatment because the underlying estrogen deficiency is ongoing.

• Vaginal estrogen — the most effective and evidence-based treatment for GSM. Applied directly to vaginal tissue as a cream, tablet, suppository, or ring, vaginal estrogen restores tissue thickness, blood flow, lubrication, and microbiome health. Systemic absorption is minimal — the doses used are a fraction of systemic doses — and vaginal estrogen is considered safe for most women, including many who are not candidates for systemic hormone therapy due to breast cancer history or other contraindications. This should be discussed with your provider based on your individual history.

• Vaginal DHEA (prasterone) — a vaginal insert that converts locally to both estrogen and testosterone in vaginal tissue. Approved by the FDA for painful intercourse related to menopause. Particularly useful for women who want to avoid direct vaginal estrogen or who are not responding fully to estrogen alone.

• Ospemifene — an oral selective estrogen receptor modulator (SERM) approved for dyspareunia related to GSM in women who prefer not to use vaginal products. Has estrogen-like effects on vaginal tissue and estrogen-neutral or estrogen-antagonist effects in breast tissue.

• Systemic hormone therapy — for women already using systemic estrogen for other menopausal symptoms, systemic therapy will also address GSM, though some women require additional vaginal estrogen for full tissue restoration.

• Testosterone — local and systemic testosterone contributes to genital blood flow, sensation, arousal response, and orgasmic function. For women whose primary concern is sexual response rather than tissue symptoms alone, testosterone is an important part of the conversation.

• Moisturizers and lubricants — non-hormonal vaginal moisturizers used regularly (not just during sex) help maintain tissue hydration and comfort. They do not restore tissue structure or treat the underlying atrophy, but they are useful adjuncts and appropriate for women who cannot or choose not to use hormonal treatment. Lubricants during intercourse reduce friction and discomfort but similarly do not address the underlying tissue changes.

• Pelvic floor physical therapy — for women with significant pelvic floor dysfunction, pain with intercourse related to muscle guarding, or stress incontinence, pelvic floor physical therapy is an important component of treatment alongside hormonal support.

The sexual function piece — naming it directly

Pain with intercourse, reduced arousal, difficulty reaching orgasm, and low libido are medical symptoms. They belong in clinical conversations exactly as much as hot flashes or sleep disruption. They affect relationships, self-image, quality of life, and mental health in ways that are significant and real.

The physiology is straightforward: estrogen maintains the vascular engorgement response that produces genital swelling and lubrication during arousal. Testosterone drives desire, clitoral sensitivity, and the capacity for orgasm. When both hormones decline, sexual function changes — not because of psychology, age, or relationship factors, but because the biological substrate for sexual response has been altered.

Treatment directed at the biological substrate — restoring estrogen to vaginal tissue, restoring testosterone where it has declined — frequently restores sexual function in ways that feel dramatic to women who assumed this was permanent. It is not permanent. It is treatable.

If you have not been asked about your sexual function at your gynecological or primary care appointments, you can raise it directly. A provider who specializes in women’s hormone health will expect this conversation and will have specific, evidence-based options to offer you.

The bottom line

Genitourinary syndrome of menopause is common, progressive, underreported, and highly treatable. The tissue changes are real, they have a clear biological cause, and “use a lubricant” is not adequate treatment for a condition with this much impact on quality of life.

Vaginal dryness is not trivial. Painful sex is not something you owe to aging. Bladder urgency that disrupts your sleep and your day has a mechanism and a solution. Recurrent UTIs that keep coming back deserve an explanation, not just another antibiotic.

You do not have to just live with any of this.

You don't have to live with this.

Book a Discovery Call or Initial Consult with Leslie, APRN

Virtual Visit $250 for 60 minutes

www.optimizeandelevate.com

This article is for educational purposes only and does not constitute medical advice. Genitourinary symptoms have multiple potential causes and should be evaluated by a qualified healthcare provider. Treatment decisions, including the use of hormone therapy, require individualized assessment based on your personal health history.